ArticlePloS one2014
The relation of hepcidin to iron disorders, inflammation and hemoglobin in chronic kidney disease.
Article in PloS one, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Cited by 37 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
37 citing papers in PubMed, 66 citations in OpenAlex.
- The effect of high-dose vitamin D supplementation on hepcidin-25 and erythropoiesis in patients with chronic kidney disease.BMC nephrology · 2023Trial
- Pilot study of the effect of cholecalciferol supplementation on hepcidin in children with chronic kidney disease: Results of the D-fense Trial.Pediatric nephrology (Berlin, Germany) · 2017Trial
- Hepcidin Response to Iron Therapy in Patients with Non-Dialysis Dependent CKD: An Analysis of the FIND-CKD Trial.PloS one · 2016Trial
- Serum hepcidin and erythropoietin in relation to anemia in non-diabetic chronic kidney disease: a cross-sectional study.Scientific reports · 2026Article
- Hepcidin as a Molecular Hub of Iron Homeostasis: From BMP-SMAD Signaling to Therapeutic Modulation.Biomolecules · 2026Review
- Erythroferrone is associated with the hepcidin-to-ferritin ratio and cardiovascular mortality in chronic kidney disease.Clinical kidney journal · 2026Article
- Association between PCV and degree of azotemia with serum hepcidin concentration in cats with chronic kidney disease.Journal of veterinary internal medicine · 2026Article
- Article
- A Recombinant Antibody Against ALK2 Promotes Tissue Iron Redistribution and Contributes to Anemia Resolution in a Mouse Model of Anemia of Inflammation.American journal of hematology · 2025Article
- Role of Nutrients in Pediatric Non-Dialysis Chronic Kidney Disease: From Pathogenesis to Correct Supplementation.Biomedicines · 2024Review
- Factors Governing the Erythropoietic Response to Intravenous Iron Infusion in Patients with Chronic Kidney Disease: A Retrospective Cohort Study.Biomedicines · 2023Article
- Hepcidin and erythroferrone response to 3 weeks of exposure to normobaric hypoxia at rest in trained cyclists.Frontiers in physiology · 2023Article
- Benefits and risks of essential trace elements in chronic kidney disease: a narrative review.Annals of translational medicine · 2022Review
- Clinical interpretation of serum hepcidin-25 in inflammation and renal dysfunction.Journal of mass spectrometry and advances in the clinical lab · 2022Article
- Safety of Intravenous Iron in CKD Stage 3-5 Patients Not on Dialysis: A Retrospective Cohort Study.Canadian journal of kidney health and disease · 2022Article
- Iron deficiency, with and without anaemia, across strata of kidney function in kidney transplant recipients.Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association · 2021Article
- Biomarkers of iron metabolism in chronic kidney disease.International urology and nephrology · 2021Review
- Treatment of anemia in difficult-to-manage patients with chronic kidney disease.Kidney international supplements · 2021Article
- The potential role of Na-K-ATPase and its signaling in the development of anemia in chronic kidney disease.American journal of physiology. Renal physiology · 2021Review
- Authors' Reply.Journal of the American Society of Nephrology : JASN · 2020Article
Corrections and comments
- Erratum issuedCorrection: The relation of hepcidin to iron disorders, inflammation and hemoglobin in chronic kidney disease.2015 · Mercadel, Lucile [corrected to Mercadal, Lucile]
Authors and funding
12 authors at 5 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The metabolism of hepcidin is profoundly modified in chronic kidney disease (CKD). We investigated its relation to iron disorders, inflammation and hemoglobin (Hb) level in 199 non-dialyzed, non-transplanted patients with CKD stages 1-5. All had their glomerular filtration rate measured by 51Cr-EDTA renal clearance (mGFR), as well as measurements of iron markers including hepcidin and of erythropoietin (EPO). Hepcidin varied from 0.2 to 193 ng/mL. The median increased from 23.3 ng/mL [8.8-28.7] to 36.1 ng/mL [14.1-92.3] when mGFR decreased from ≥60 to <15 mL/min/1.73 m2 (p = 0.02). Patients with absolute iron deficiency (transferrin saturation (TSAT) <20% and ferritin <40 ng/mL) had the lowest hepcidin levels (5.0 ng/mL [0.7-11.7]), and those with a normal iron profile (TSAT ≥20% and ferritin ≥40), the highest (34.5 ng/mL [23.7-51.6]). In multivariate analysis, absolute iron deficiency was associated with lower hepcidin values, and inflammation combined with a normal or functional iron profile with higher values, independent of other determinants of hepcidin concentration, including EPO, mGFR, and albuminemia. The hepcidin level, although it rose overall when mGFR declined, collapsed in patients with absolute iron deficiency. There was a significant interaction with iron status in the association between Hb and hepcidin. Except in absolute iron deficiency, hepcidin's negative association with Hb level indicates that it is not down-regulated in CKD anemia.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.